Published in Mol Cell Biol on June 09, 2008
GCPII imaging and cancer. Curr Med Chem (2012) 1.12
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling. Mol Cancer (2015) 0.86
Group I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases. Front Pharmacol (2012) 0.86
Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor. Pigment Cell Melanoma Res (2014) 0.85
Atypical mechanism of NF-κB activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis. Oncogene (2011) 0.84
Noise Stress Induces an Epidermal Growth Factor Receptor/Xeroderma Pigmentosum-A Response in the Auditory Nerve. J Histochem Cytochem (2016) 0.75
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 20.70
Signaling to NF-kappaB. Genes Dev (2004) 19.78
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem (1999) 5.16
Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell (2003) 4.37
Glutamate release promotes growth of malignant gliomas. Nat Med (2001) 3.67
NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci (2003) 3.40
Calcium and neurodegeneration. Aging Cell (2007) 2.90
Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ (2006) 2.67
Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med (2003) 2.49
Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem (2005) 2.30
Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A (2001) 1.88
A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol (2005) 1.73
GABA and glutamate in the human brain. Neuroscientist (2002) 1.69
Signaling via NF-kappaB in the nervous system. Biochim Biophys Acta (2005) 1.63
CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes Dev (2007) 1.45
Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors. Nature (1996) 1.43
Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J (2005) 1.36
Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene (2007) 1.36
Ras regulation of NF-kappa B and apoptosis. Methods Enzymol (2001) 1.30
Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci (2006) 1.29
NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol (2006) 1.26
Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol (2007) 1.22
Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience (2005) 1.16
Metabotropic glutamate receptors in stem/progenitor cells. Neuropharmacology (2007) 1.01
Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J Neurosci (2001) 0.99
Ionotropic glutamate receptors in astrocytes. Prog Brain Res (2001) 0.98
Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. Glia (2007) 0.98
Expression of metabotropic glutamate receptor 5 is increased in astrocytes after kainate-induced epileptic seizures. Glia (2000) 0.94
Acute up-regulation of glutamate uptake mediated by mGluR5a in reactive astrocytes. J Neurochem (2005) 0.92
PYK2 links G(q)alpha and G(13)alpha signaling to NF-kappa B activation. J Biol Chem (2001) 0.91
Glial glutamate receptors: likely actors in brain signaling. FASEB J (1991) 0.89
Nuclear factor-kappab activation is associated with glutamate-evoked tissue transglutaminase up-regulation in primary astrocyte cultures. J Neurosci Res (2005) 0.84
Roles of metabotropic glutamate receptors in glial function and glial-neuronal communication. J Neurosci Res (1996) 0.82
Autocrine activation of EGF receptor promotes oscillation of glutamate-induced calcium increase in astrocytes cultured in rat cerebral cortex. J Neurochem (2005) 0.80
Glutamate promotes NF-kappaB pathway in primary astrocytes: protective effects of IRFI 016, a synthetic vitamin E analogue. Exp Neurol (2005) 0.80
Mechanisms of glutamate receptor induced proliferation of astrocytes. Neuroreport (2006) 0.78
NMDA-responsible, APV-insensitive receptor in cultured human astrocytes. Life Sci (2001) 0.78
A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature (2003) 4.18
NF-kappaB as a therapeutic target in cancer. Trends Mol Med (2002) 3.08
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev (2008) 2.89
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev (2004) 2.51
Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol (2005) 2.18
Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol (2008) 1.95
Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol (2004) 1.79
Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res (2010) 1.78
p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol Cell (2012) 1.76
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood (2006) 1.71
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res (2004) 1.65
IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem (2006) 1.57
Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res (2008) 1.51
Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2007) 1.50
LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell (2007) 1.47
Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev (2005) 1.42
NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. J Biol Chem (2002) 1.37
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol (2002) 1.37
Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J (2005) 1.36
Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood (2004) 1.35
Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression. Proc Natl Acad Sci U S A (2008) 1.35
Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol (2002) 1.35
Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res (2007) 1.34
NF-kappaB mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism. Genes Dev (2003) 1.33
Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem (2012) 1.28
IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. PLoS One (2010) 1.22
Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol (2007) 1.22
IkappaB kinase alpha and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of IkappaBalpha degradation. J Biol Chem (2004) 1.20
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res (2012) 1.19
The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res (2004) 1.19
Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli. Immunity (2010) 1.17
PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem (2002) 1.15
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood (2012) 1.15
Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol (2008) 1.15
GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov (2013) 1.13
Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med (2011) 1.09
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol (2003) 1.06
The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser10 phosphorylation. J Biol Chem (2006) 1.05
Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood (2013) 1.02
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res (2012) 1.01
Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. Cancer Res (2004) 1.01
Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One (2009) 1.01
NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res (2011) 1.00
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLoS One (2013) 0.99
Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway. Hepatology (2009) 0.96
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther (2008) 0.96
Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol (2012) 0.95
NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology (2010) 0.95
Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε. PLoS One (2012) 0.95
Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther (2008) 0.94
Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. J Cell Biol (2013) 0.93
Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology (2007) 0.92
Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol (2006) 0.91
NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J Immunol (2003) 0.89
MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol (2013) 0.88
NF-kappaB pathways in the immune system: control of the germinal center reaction. Immunol Res (2008) 0.86
Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion. J Immunol (2007) 0.85
C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction. Mol Cancer Res (2011) 0.85
Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther (2013) 0.85
Monoallelic deletion of NFKBIA in glioblastoma: when less is more. Cancer Cell (2011) 0.84
Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J Thorac Cardiovasc Surg (2008) 0.83
Observing single cell NF-κB dynamics under stimulant concentration gradient. Anal Chem (2012) 0.82
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Res (2009) 0.81
Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int J Radiat Oncol Biol Phys (2010) 0.79
Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways. J Biol Chem (2003) 0.79
Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. Nucleic Acids Res (2007) 0.78
Nuclear factor-kappaB activation in endothelium by Chlamydia pneumoniae without active infection. J Infect Dis (2003) 0.78
Regulation of NF-kappaB by oncoproteins and tumor suppressor proteins. Methods Mol Biol (2003) 0.76
Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease. Eur J Immunol (2014) 0.75
Using RNA interference in lung cancer cells to target the IKK-NF-κB pathway. Methods Mol Biol (2015) 0.75